Share chart Quidel
Extended chart
Simple chart
About Quidel
Quidel Corporation - крупный американский производитель диагностических медицинских продуктов, которые продаются по всему миру. 8 мая 2020 года Управление по санитарному надзору за качеством пищевых продуктов и медикаментов США (FDA) выдало первое разрешение на использование в экстренных случаях (EUA) для теста на антиген COVID-19, новой категории тестов для использования в условиях продолжающейся пандемии. Эти диагностические тесты быстро обнаруживают фрагменты белков, обнаруженных на вирусе или внутри него, путем тестирования образцов, взятых из носовой полости, с помощью мазков.Main settings
IPO date
1991-02-01
ISIN
US2197981051
Industry
Health Care Equipment & Supplies
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 1.06 | 9 |
| P/BV | 0.9907 | 9 |
| P/E | 8.86 | 9 |
Efficiency
| Title | Value | Grade |
| ROA | -27.38 | 0 |
| ROE | -51.36 | 0 |
| ROIC | 48.08 | 10 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -1.84 | 10 |
| Debt/Ratio | 0.4174 | 10 |
| Debt/Equity | 1.15 | 8 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 67.64 | 8 |
| Yield Ebitda, % | -237.84 | 0 |
| Yield EPS, % | -264.26 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 29.88 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 29.53 $ | 0 $ | 0 $ | 1.19 % | 0 % | 0 % |
| Month | 30.18 $ | 29.53 $ | 31.7 $ | -0.99 % | 0 % | 0 % |
| Three month | 28.85 $ | 24.46 $ | 37.42 $ | 3.57 % | 0 % | 0 % |
| Half a year | 42.74 $ | 24.46 $ | 47.61 $ | -30.09 % | 0 % | 0 % |
| Year | 44.33 $ | 24.46 $ | 47.61 $ | -32.6 % | 0 % | 0 % |
| 3 years | 82.3 $ | 24.46 $ | 107.07 $ | -63.69 % | 0 % | 0 % |
| 5 years | 137.13 $ | 24.46 $ | 301.96 $ | -78.21 % | 0 % | 0 % |
| 10 years | 22.72 $ | 13.87 $ | 301.96 $ | 31.51 % | 0 % | 0 % |
| Year to date | 42.89 $ | 24.46 $ | 47.61 $ | -30.33 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| Carlyle Group Inc. | 12 460 183 | 18.63 |
| T. Rowe Price Investment Management, Inc. | 8 698 143 | 13.01 |
| Vanguard Group Inc | 4 841 410 | 7.24 |
| Blackrock Inc. | 4 798 164 | 7.17 |
| Senvest Management LLC | 2 999 353 | 4.48 |
| ArrowMark Colorado Holdings LLC | 2 663 606 | 3.98 |
| State Street Corporation | 1 530 817 | 2.29 |
| JP Morgan Chase & Company | 1 335 012 | 2 |
| Burgundy Asset Management Ltd. | 1 161 485 | 1.74 |
| Rubric Capital Management LP | 980 063 | 1.47 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| Amplify Treatments Testing and Advancements ETF | 3.55 | 3 | 0.68 |
| iShares Morningstar Small-Cap Value ETF | 0.10014 | 193.7 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.04986 | 328.78 | 0.25 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Robert J. Bujarski J.D. | Executive VP & COO | 2.62M | 1969 (56 years) |
| Dr. Werner Kroll Ph.D. | Senior Vice President of Research & Development | 1.25M | 1957 (68 years) |
| Mr. Joseph M. Busky CPA | Chief Financial Officer | 1.47M | 1968 (57 years) |
| Mr. Michael S. Iskra | Executive VP & Chief Commercial Officer | N/A | 1970 (55 years) |
| Mr. William J. Ferenczy | Point of Care Business Unit Leader | N/A | 1956 (69 years) |
| Ms. Tamara A. Ranalli | Molecular Diagnostics Business Unit Leader | N/A | 1973 (52 years) |
| Mr. Brian J. Blaser | President, CEO & Director | 1965 (60 years) | |
| Ms. Juliet C. Cunningham | Vice President of Investor Relations | ||
| Ms. Michelle A. Hodges J.D. | Senior VP, General Counsel & Corporate Secretary | 1963 (62 years) | |
| Mr. Ronald Lee Bowman | Chief Human Resources Officer |
About company
Address: United States, San Diego, 9975 Summers Ridge Road - Open in google maps, Open in yandex maps
Website: http://www.quidel.com
Website: http://www.quidel.com
